KPTIQKaryopharm Therapeutics Inc.
Earnings
When Karyopharm Therapeutics Inc. reports, what it reported each quarter, and how the stock took the results.
58 quarters. Mar 31, 2012 to Jun 30, 2026. USD.
Next results · Q3 2026Window passed
No 10-Q yet
Mon, Nov 2, 202615 days ago
The 10-Q window, Nov 2 – 16, passed with no filing on file.
- Quarter
- Q3 2026 · Ended Sep 30, 2026
- 10-Q window
- Nov 2 – 16
Read against Q3 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $44.04M
- Revenue, change from a year earlier: Q2 2026 −11.9%, Q1 2026 +16.8%, Q4 2025 +11.6%, Q3 2025 +13.6%
- Net income
- -$33.13M
- Net income, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m, Q3 2025 n/m
- EPS
- -$3.82
- EPS, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m, Q2 2025 n/m
Latest results
- Revenue
- $33.43M
- −11.9%
- Net income
- -$67.02M
- N/M
- EPS
- -$2.32
- N/M
- Revenue
- $35.07M
- +16.8%
- Net income
- -$22.39M
- N/M
- EPS
- -$1.24
- N/M
- Revenue
- $34.08M
- +11.6%
- Net income
- -$102.20M
- N/M
- EPS
- —
- —
- Revenue
- $44.04M
- +13.6%
- Net income
- -$33.13M
- N/M
- EPS
- -$3.82
- N/M
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q2 2026 | Jun 30, 2026 | Aug 13, 2026 · pre-market | Aug 13, 2026 | 44 d | 10-Q | $33.43M | −11.9% | -$2.32 | — | |
| Q1 2026 | Mar 31, 2026 | May 14, 2026 · pre-market | May 14, 2026 | 44 d | 10-Q | $35.07M | +16.8% | -$1.24 | — | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Feb 12, 2026 · pre-market | Feb 13, 2026 | 44 d | 10-K | $34.08M | +11.6% | — | — | |
| Q3 2025 | Sep 30, 2025 | Nov 3, 2025 · pre-market | Nov 3, 2025 | 34 d | 10-Q | $44.04M | +13.6% | -$3.82 | — | |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 · pre-market | Aug 11, 2025 | 42 d | 10-Q | $37.93M | −11.4% | -$4.32 | — | |
| Q1 2025 | Mar 31, 2025 | May 12, 2025 · after-hours | May 12, 2025 | 42 d | 10-Q | $30.02M | −9.4% | -$2.77 | — | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Feb 19, 2025 · pre-market | Feb 19, 2025 | 50 d | 10-K | $30.54M | −9.5% | — | — | |
| Q3 2024 | Sep 30, 2024 | Nov 5, 2024 · pre-market | Nov 5, 2024 | 36 d | 10-Q | $38.78M | +7.7% | -$3.85 | — | |
| Q2 2024 | Jun 30, 2024 | Aug 6, 2024 · pre-market | Aug 6, 2024 | 37 d | 10-Q | $42.79M | +13.9% | -$2.97 | — | |
| Q1 2024 | Mar 31, 2024 | May 8, 2024 · pre-market | May 8, 2024 | 38 d | 10-Q | $33.13M | −14.4% | -$4.85 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Feb 29, 2024 · pre-market | Feb 29, 2024 | 60 d | 10-K | $33.75M | +0.5% | — | — | |
| Q3 2023 | Sep 30, 2023 | Nov 2, 2023 · pre-market | Nov 2, 2023 | 33 d | 10-Q | $36.01M | −0.4% | -$0.30 | — | |
| Q2 2023 | Jun 30, 2023 | Aug 2, 2023 · pre-market | Aug 2, 2023 | 33 d | 10-Q | $37.58M | −5.3% | -$0.29 | — | |
| Q1 2023 | Mar 31, 2023 | May 4, 2023 · pre-market | May 4, 2023 | 34 d | 10-Q | $38.70M | −18.8% | -$0.30 | — | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Feb 15, 2023 · pre-market | Feb 17, 2023 | 48 d | 10-K | $33.58M | −73.4% | — | — | |
| Q3 2022 | Sep 30, 2022 | Nov 3, 2022 · after-hours | Nov 3, 2022 | 34 d | 10-Q | $36.15M | −4.1% | -$0.45 | — | |
| Q2 2022 | Jun 30, 2022 | Aug 4, 2022 · pre-market | Aug 4, 2022 | 35 d | 10-Q | $39.68M | +75.6% | -$0.62 | — | |
| Q1 2022 | Mar 31, 2022 | May 5, 2022 · pre-market | May 5, 2022 | 35 d | 10-Q | $47.67M | +104.9% | -$0.53 | — | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Feb 8, 2022 · pre-market | Mar 1, 2022 | 60 d | 10-K | $126.27M | +259.7% | — | — | |
| Q3 2021 | Sep 30, 2021 | Nov 3, 2021 · pre-market | Nov 3, 2021 | 34 d | 10-Q | $37.69M | +76.7% | -$0.69 | — | |
| Q2 2021 | Jun 30, 2021 | Aug 5, 2021 · pre-market | Aug 5, 2021 | 36 d | 10-Q | $22.60M | −32.6% | -$0.71 | — | |
| Q1 2021 | Mar 31, 2021 | May 3, 2021 · pre-market | May 4, 2021 | 34 d | 10-Q | $23.26M | +28.2% | -$0.77 | — | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | Feb 11, 2021 · pre-market | Feb 24, 2021 | 55 d | 10-K | $35.10M | +94.0% | — | — | |
| Q3 2020 | Sep 30, 2020 | Nov 2, 2020 · after-hours | Nov 2, 2020 | 33 d | 10-Q | $21.33M | +62.2% | -$0.73 | — | |
| Q2 2020 | Jun 30, 2020 | Aug 4, 2020 · pre-market | Aug 4, 2020 | 35 d | 10-Q | $33.51M | +253.0% | -$0.63 | — | |
| Q1 2020 | Mar 31, 2020 | May 5, 2020 · pre-market | May 5, 2020 | 35 d | 10-Q | $18.14M | +11,601.9% | -$0.78 | — | |
| FY 2019 | ||||||||||
| Q4 2019derived | Dec 31, 2019 | Feb 13, 2020 · pre-market | Feb 26, 2020 | 57 d | 10-K | $18.10M | +8,684.5% | — | — | |
| Q3 2019 | Sep 30, 2019 | Nov 4, 2019 · pre-market | Nov 4, 2019 | 35 d | 10-Q | $13.15M | +5,401.7% | -$0.67 | — | |
| Q2 2019 | Jun 30, 2019 | Aug 6, 2019 · pre-market | Aug 7, 2019 | 38 d | 10-Q | $9.49M | −52.3% | -$0.71 | — | |
| Q1 2019 | Mar 31, 2019 | May 9, 2019 · pre-market | May 9, 2019 | 39 d | 10-Q | $155.00K | −98.5% | -$1.09 | — | |
| FY 2018 | ||||||||||
| Q4 2018 | Dec 31, 2018 | Feb 28, 2019 · pre-market | Feb 28, 2019 | 59 d | 10-K | $206.00K | −86.6% | -$0.96 | — | |
| Q3 2018 | Sep 30, 2018 | — | Nov 8, 2018 | 39 d | 10-Q | $239.00K | — | -$0.79 | — | |
| Q2 2018 | Jun 30, 2018 | — | Aug 7, 2018 | 38 d | 10-Q | $19.89M | +662,933.3% | -$0.60 | — | |
| Q1 2018 | Mar 31, 2018 | — | May 10, 2018 | 40 d | 10-Q | $10.00M | +14,605.9% | -$0.78 | — | |
| FY 2017 | ||||||||||
| Q4 2017 | Dec 31, 2017 | — | Mar 15, 2018 | 74 d | 10-K | $1.53M | +3,163.8% | -$0.80 | — | |
| Q3 2017 | Sep 30, 2017 | — | Nov 2, 2017 | 33 d | 10-Q | $0.00 | −100.0% | -$0.65 | — | |
| Q2 2017 | Jun 30, 2017 | — | Aug 8, 2017 | 39 d | 10-Q | $3.00K | −94.9% | -$0.64 | — | |
| Q1 2017 | Mar 31, 2017 | — | May 4, 2017 | 34 d | 10-Q | $68.00K | — | -$0.71 | — | |
| FY 2016 | ||||||||||
| Q4 2016 | Dec 31, 2016 | — | Mar 16, 2017 | 75 d | 10-K | $47.00K | +88.0% | -$0.65 | — | |
| Q3 2016 | Sep 30, 2016 | — | Nov 7, 2016 | 38 d | 10-Q | $48.00K | −36.0% | -$0.69 | — | |
| Q2 2016 | Jun 30, 2016 | — | Aug 4, 2016 | 35 d | 10-Q | $59.00K | −60.7% | -$0.84 | — | |
| Q1 2016 | Mar 31, 2016 | — | May 9, 2016 | 39 d | 10-Q | — | — | -$0.75 | — | |
| FY 2015 | ||||||||||
| Q4 2015 | Dec 31, 2015 | — | Mar 15, 2016 | 75 d | 10-K | $25.00K | +56.3% | -$0.81 | — | |
| Q3 2015 | Sep 30, 2015 | — | Nov 9, 2015 | 40 d | 10-Q | $75.00K | +257.1% | -$0.85 | — | |
| Q2 2015 | Jun 30, 2015 | — | Aug 10, 2015 | 41 d | 10-Q | $150.00K | +614.3% | -$0.92 | — | |
| Q1 2015 | Mar 31, 2015 | — | May 11, 2015 | 41 d | 10-Q | — | — | -$0.74 | — | |
| FY 2014 | ||||||||||
| Q4 2014 | Dec 31, 2014 | — | Mar 13, 2015 | 72 d | 10-K | $16.00K | −23.8% | -$0.79 | — | |
| Q3 2014 | Sep 30, 2014 | — | — | — | — | $21.00K | — | -$0.61 | — | |
| Q2 2014 | Jun 30, 2014 | — | — | — | — | $21.00K | −84.2% | -$0.55 | — | |
| Q1 2014 | Mar 31, 2014 | — | — | — | — | $171.00K | −26.6% | -$0.46 | — | |
| FY 2013 | ||||||||||
| Q4 2013 | Dec 31, 2013 | — | — | — | — | $21.00K | −36.4% | -$0.72 | — | |
| Q3 2013 | Sep 30, 2013 | — | — | — | — | $0.00 | −100.0% | -$3.66 | — | |
| Q2 2013 | Jun 30, 2013 | — | — | — | — | $133.00K | −75.0% | -$2.86 | — | |
| Q1 2013 | Mar 31, 2013 | — | — | — | — | $233.00K | +585.3% | -$2.52 | — | |
| FY 2012 | ||||||||||
| Q4 2012 | Dec 31, 2012 | — | — | — | — | $33.00K | — | -$2.08 | — | |
| Q3 2012 | Sep 30, 2012 | — | — | — | — | $34.00K | — | -$1.97 | — | |
| Q2 2012 | Jun 30, 2012 | — | — | — | — | $533.00K | — | -$2.37 | — | |
| Q1 2012 | Mar 31, 2012 | — | — | — | — | $34.00K | — | -$2.71 | — | |
Earlier years, FY 2012 to FY 2023The latest three years
Source filings
Provenance
ProvenanceData status and checks
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR